Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)

Kerbrat, Pierre; Desmoulins, Isabelle; Roca, Lise; Lévy, Christelle; Lortholary, Alain; Marre, A.; Delva, R.; Rios, María; Viens, Patrice; Brain, Étienne; Serin, D.; Edel, Magali; Debled, Marc; Campone, Mario; Mourret-Reynier, Marie-Ange; Bachelot, Thomas; Foucher-Goudier, Marie-Josèphe; Asselain, Bernard; Lemonnier, Jérôme; Martin, Anne‐Laure; Roché, Henri

doi:10.1016/j.ejca.2017.03.004

Cited by 7 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the progress in medical scientific research and the increase in clinical trials, researchers constantly optimize the selection of chemotherapy regimens to achieve the best survival time and minimum adverse reactions. For example, Kerbrat's group conducted a randomized phase III trial comparing six cycles of 5-fluorouracil, epirubicin, and CTX (FEC) to four cycles of adriamycin and CTX (AC) in patients with breast cancer, and showed that there was no significance in both disease-free survival and overall survival between the FEC and AC regimens, while reproductive toxicity was more severe in the FEC regimen (5). These results indicate that four cycles of the AC regimen for breast cancer treatment inflict less damage on ovarian function.…”

Section: Choice Of Chemotherapy Regimenmentioning

confidence: 99%

THERAPY OF ENDOCRINE DISEASE: Novel protection and treatment strategies for chemotherapy-associated ovarian damage

Xiong

Xue

et al. 2021

European Journal of Endocrinology

View full text Add to dashboard Cite

Fertility and ovarian protection against chemotherapy-associated ovarian damage has formed a new field called oncofertility, which is driven by the pursuit of fertility protection as well as good life quality by numerous female cancer survivors. However, the choice of fertility and ovarian protection method is a difficult problem during chemotherapy and there is no uniform guideline at present. To alleviate ovarian toxicity caused by anticancer drugs, effective methods combined with individualized treatment that integrate an optimal strategy for preserving and restoring reproductive function should be offered from well-established to experimental stages before, during, and after chemotherapy. Although embryo, oocyte, and ovarian tissue cryopreservation are the major methods that have been proven effective and feasible for fertility protection, they are also subject to many limitations. Therefore, this paper mainly discusses the future potential methods and corresponding mechanisms for fertility protection in chemotherapy-associated ovarian damage.

show abstract

Section: Choice Of Chemotherapy Regimenmentioning

confidence: 99%

THERAPY OF ENDOCRINE DISEASE: Novel protection and treatment strategies for chemotherapy-associated ovarian damage

Xiong

Xue

et al. 2021

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…On the one hand, some phase III trials did not show significant differences between shorter and longer adjuvant ChT duration in limited-stage BC patients. [27][28][29] On the other hand, none of these studies was conducted in the neoadjuvant setting, and most of them did not use anthracycline-taxane concomitant or sequential treatments, thus reducing their informative potential in the current clinical scenario. Finally, in those studies that compared neoadjuvant ChT regimens of different duration, different cytotoxic compounds and treatment schemes were used, thus limiting the possibility to draw definitive conclusions about the clinical impact of modifying treatment duration.…”

Section: Introductionmentioning

confidence: 99%

Antitumor activity and efficacy of shorterversuslonger duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis

et al. 2020

View full text Add to dashboard Cite

Background: Neoadjuvant anthracycline-taxane-based chemotherapy (ChT) is a standard of care treatment option for stage II–III breast cancer (BC) patients. However, the optimal duration of neoadjuvant ChT has been poorly investigated so far. Material and methods: We retrospectively retrieved clinical data of patients with stage II–III human epidermal growth factor receptor 2-negative (HER2–) BC who were treated between October 2007 and January 2018 with neoadjuvant AT (doxorubicin-paclitaxel) for three cycles followed by CMF (cyclophosphamide-methotrexate-5-fluorouracil) for three cycles (cohort A) or with four AT cycles followed by four CMF cycles (cohort B). The aim of our study was to investigate the impact of neoadjuvant ChT duration (cohort A versus cohort B) on pathological complete response (pCR) rates, disease-free survival (DFS) and overall survival (OS). Results: Of 209 HER2– BC patients included, 62 had triple-negative breast cancer (TNBC) and 147 had hormone receptor-positive (HR+) BC. Median age was 48 years (range 30–74 years). A total of 111 patients belonged to cohort A and 98 patients belonged to cohort B. pCR was detected in 29 (13.9%) patients, 25 (40.3%) of whom had TNBC and four (2.7%) had HR+ HER2– BC. Patients achieving pCR had significantly longer DFS and OS, with statistical significance reached only in patients with TNBC. We found no differences between cohort A and cohort B in terms of pCR rates (15.3% versus 12.2%; p = 0.55), DFS ( p = 0.49) or OS ( p = 0.94). The incidence of grade 3/4 adverse events was similar in cohort A versus cohort B as well (22.5% versus 19.4%; p = 0.54). Conclusion: Shorter duration of neoadjuvant anthracycline-taxane ChT was not associated with worse clinical outcomes in patients with stage II–III BC. Prospective studies are needed to evaluate whether the duration of neoadjuvant anthracycline-taxane-based ChT can be reduced in specific patient subgroups without negatively affecting clinical outcomes.

show abstract

Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer

et al. 2019

View full text Add to dashboard Cite

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)

Cited by 7 publications

References 31 publications

THERAPY OF ENDOCRINE DISEASE: Novel protection and treatment strategies for chemotherapy-associated ovarian damage

THERAPY OF ENDOCRINE DISEASE: Novel protection and treatment strategies for chemotherapy-associated ovarian damage

Antitumor activity and efficacy of shorterversuslonger duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis

Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer

Contact Info

Product

Resources

About